The Efficacy of oral dutasteride in the treatment of female pattern androgenetic alopecia
Phase 3
- Conditions
- Androgenitic alopecia.
- Registration Number
- IRCT20231119060107N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
?Androgenitic alopecia female patients
Exclusion Criteria
History of breast cancer
Usage of another AGA treatment in the past 3 months
Pregnancy or a plan to get ptegnant in the next year
Smoking or alchohol addiction
Drug reaction to dutasteride or spironolactone
History of hair transplant
History of any dermatologic or systemic disease that affect hair
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hair density increase in the vertex area. Timepoint: 0, 3 months after treatment , 6 months after treament. Method of measurement: Trichoscopy report.;Hair thickness increase. Timepoint: 0, 3 months after treatment , 6 months after treament. Method of measurement: Tricoscopy report.
- Secondary Outcome Measures
Name Time Method Alopecia grade. Timepoint: 0, 3 months after treatment , 6 months after treament. Method of measurement: Sinclair scale.;Treatment response. Timepoint: 3 months after treatment , 6 months after treament. Method of measurement: Questionnaire.;Patient quality of life. Timepoint: 0, 3 months after treatment , 6 months after treament. Method of measurement: Dermatology life Quality Index questionnaire.;Drug complications. Timepoint: 1 month after treatment, 3 months after treatment , 6 months after treament. Method of measurement: Questionnaire.;Villus and terminal hair number. Timepoint: 0, 3 months after treatment , 6 months after treament. Method of measurement: Trichoscopy report.